First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

October 30, 2027

Conditions

Ovarian CancerHigh Grade Serous Adenocarcinoma of OvaryHigh Grade Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian-tube Cancer

Interventions

DRUG

Fluzoparib Capsules

oral

DRUG

Bevacizumab

Injectable solution

Trial Locations (1)

Sun Yat-sen University Cancer Cetntre, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER